¢£·Ç¼¨ÈĤËÌá¤ë¢£ Á´Éô 1- ºÇ¿·50
¥¬¥óÊݸ±¡¡¡¡ÏÀʸʣ¼Ì¤Ø¡¡´â¥ê¥ó¥¯¤Ø¡¡´â¼­Åµ¤Ø¡¡

´â·Ç¼¨ÈÄ..>¹üž°Ü¡¡Êü¼ÍÀþ¤Ê¤É¤ÎÎɤ¤É±¡¤ò¶µ¤¨¤Æ¤¯¤À¤µ¤¤

1 ̾Á°¡§ ´â¤ËÉ餱¤Ê¤¤ Åê¹ÆÆü¡§2006/08/05(ÅÚ) 14:58
º£Æü¤Ï¡¡
É㤬ºòǯ4·î¤Ëç¹Â¡¤¬¤ó¤Î¼ê½Ñ¡¦12·î¤Ë¤âÉû¿ÕŦ½Ð¤Î¼ê½Ñ¤ò¼õ¤±¤Þ¤·¤¿¡£º£¤Î¤È¤³¤íÆâ¡¤Ë¤Ï¤½¤Î¾¤Îž°Ü¤Ï¸«¤é¤ì¤Ê¤¤¤Î¤Ç¤¹¤¬
¹üž°Ü¤·¤Æ¤¤¤Æ¡¢ÂçÂܹü¤ÈÂè5¹øÄǤËž°Ü¤¬¸«¤é¤ì¤Þ¤¹¡£
¼ê½Ñ¤Î¸å¤Ï¥¸¥§¥à¥¶¡¼¥ë¤ò³¤±¤Æ¤­¤Þ¤·¤¿¤¬¡¢¥Þ¡¼¥«¡¼¤Ë¤ÏÁ´¤¯¸ú²Ì¤¬¤Ê¤¯¡¢º£¤Ï3000¤Ë¤â¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£

º£¤Þ¤Ç¼ê½Ñ¤Ê¤É¤ò¤·¤Æ¤­¤¿É±¡¤ÏÊü¼ÍÀþ¤È³°²Ê¤ÎÏ¢·È¤â°­¤¯¡¢¤¢¤Þ¤ê¿Æ¿È¤Ë¤Ê¤Ã¤Æ¤¯¤ì¤Æ¤â¤¤¤Ê¤¤¤è¤¦¤Ë´¶¤¸
¹üž°Ü¡¦Êü¼ÍÀþ¼£ÎŤΤ¤¤¤É±¡¤¬¤¢¤ì¤Ðž±¡¤â¹Í¤¨¤¿¤¤¤È»×¤Ã¤Æ¤¤¤Þ¤¹¡£
¼ÂºÝ¥Ó¥¹¥Õ¥©¥¹¥Õ¥©¥Í¡¼¥È¤âç¹Â¡¤¬¤ó¤Ë¤Ï¸ú¤«¤Ê¤¤¤È¤Î»ö¤Ç¼è¤ê¾å¤²¤Æ¤â¤é¤¨¤Þ¤»¤ó¡£
´ØÀ¾¡¦¤Ç¤­¤ì¤ÐÂçºå¤«¿À¸Í¤Ç¤è¤¤É±¡¤ò¤´Â¸ÃΤǤ·¤¿¤é¶µ¤¨¤Æ¤¤¤¿¤À¤±¤Þ¤»¤ó¤Ç¤·¤ç¤¦¤«¡©
¤Þ¤¿¡¢¹üž°Ü¤Î¼£ÎÅÊýË¡¤ò¤´Â¸ÃΤÎÊý¡¢¤É¤ó¤Ê¤³¤È¤Ç¤â·ë¹½¤Ç¤¹¤Î¤Ç¶µ¤¨¤Æ¤¤¤¿¤À¤±¤¿¤é
´ò¤·¤¤¤Ç¤¹¡£
¤É¤¦¤¾¤è¤í¤·¤¯¤ª´ê¤¤¤·¤Þ¤¹¡£


2 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2007/01/23(²Ð) 16:44
¤¢¤¢¤¢¤¢
Sunitinib Malate;http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate
Sorafenib Tosylate;http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate
Temsirolimus;http://www.cancer.gov/clinicaltrials/results/sunitinib-and-temsirolimus0606

Sunitinib vs IFN;http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&index=y&abstractID=30512

3 ̾Á°¡§ ̵̾¤·¤µ¤ó@´â·Ç¼¨ÈÄ Åê¹ÆÆü¡§2007/01/23(²Ð) 16:45
¤¢¤¢¤¢¤¢¡¡
Sunitinib Malate;http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate
Sorafenib Tosylate;http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate
Temsirolimus;http://www.cancer.gov/clinicaltrials/results/sunitinib-and-temsirolimus0606

Sunitinib vs IFN;http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&index=y&abstractID=30512

4 ̾Á°¡§ ¤¨¤ë¤Ó¤¹ Åê¹ÆÆü¡§2007/07/01(Æü) 10:50
¹ü¤Ë¤Ï¤Ê¤«¤Ê¤«¹³´âºÞ¤¬¸ú¤«¤Ê¤¤¤ß¤¿¤¤¤Ç¤¹¤Í¡¢¥¬¥ó¤Ç¤â¤í¤¯¤Ê¤Ã¤¿¹ü¤òÊ䶯¤¹¤ë¤¿¤á¤Ë¡¢°åÎÅ¥³¥ó¥¯¥ê¡¼¥È¤òÃí¼Í¤¹¤ë¤È¡¢Äˤ߻ߤá¤È¡¢¥³¥ó¥¯¥ê¡¼¥È¤¬¹Å²½¤¹¤ë»þ¤Ë½Ð¤¹Ç®¤¬¡¢¥¬¥ó¤ò»àÌǤµ¤»¤ë¸ú²Ì¤¬¤¢¤ë¤È¤«Ê¹¤­¤Þ¤·¤¿¤è¡£


¼¡¡¡¿·Ãå¥ì¥¹¤Îɽ¼¨¡¡¡¡TOP¤Ø
̾Á° ¡§ E-mail(¾Êά²Ä) ¡§
Ãç´ÖƱ»Î¡¦Èó¸ø³«¤Î·Ç¼¨ÈÄ,
¥Ö¥í¥°,¥¢¥Ð¥¿¡¼,¾·ÂÔ¾õޥޥޥ
¡¡´â·Ç¼¨ÈĤο·¥³¡¼¥Ê¡¼¡¡
¡¡¤¬¤óSNS

(C) ¥¿¥«¥Ò¥í¡÷¤ß¤Á¤Î¤¯·Ç¼¨ÈÄ [12ch BBS 1.06²þ]
read.cgi²þ¦Â£±Ver.1.01